The cause and pathogenesis of the eosinophilia-myalgia syndrome
- PMID: 1727618
- DOI: 10.7326/0003-4819-116-2-140
The cause and pathogenesis of the eosinophilia-myalgia syndrome
Abstract
Objective: To review recent advances in the understanding of the cause and pathogenesis of the eosinophilia-myalgia syndrome associated with ingestion of L-tryptophan.
Data sources: Studies published from 1989 to 1991 were identified using a MEDLINE literature search. Additional references were selected from the bibliographies of identified articles.
Data synthesis: The eosinophilia-myalgia syndrome was epidemiologically associated with ingestion of L-tryptophan-containing preparations. Analysis of case-associated lots of L-tryptophan has revealed several chemical impurities. One of these, labeled "peak E," is an unusual dimeric form of L-tryptophan (1,1'-ethylidenebis[tryptophan]), and its presence is associated with the eosinophilia-myalgia syndrome (P = 0.022). Evidence of abnormal metabolism of tryptophan has been found in some patients with the syndrome. Eosinophil activation and the release of major basic protein and other eosinophil-derived toxic proteins into the extracellular space is a striking feature in the eosinophilia-myalgia syndrome and implicates eosinophils or their products in the pathogenesis. Mononuclear cell activation and infiltration of various affected tissues as well as fibrosis of the integument and of the connective tissue components of blood vessels, nerves, and muscles are additional frequent findings.
Conclusions: Current evidence suggests that the epidemic of the eosinophilia-myalgia syndrome was caused by contaminated L-tryptophan preparations originating from a single manufacturer. Peak E or other, as yet unidentified, contaminants may trigger activation of eosinophils and inflammatory cells and increase biosynthesis of connective tissue components, resulting in the clinical and pathologic manifestations of the eosinophilia-myalgia syndrome. Further studies of the interaction of eosinophils, inflammatory cells, and fibroblasts may increase the understanding of the pathogenesis of the eosinophilia-myalgia syndrome. The insights gained from the epidemic may be applicable to more common idiopathic diseases associated with eosinophilia and fibrosis.
Comment in
-
Serum cytokines and the eosinophilia myalgia syndrome.Ann Intern Med. 1992 Aug 15;117(4):344-5. doi: 10.7326/0003-4819-117-4-344. Ann Intern Med. 1992. PMID: 1463513 No abstract available.
Similar articles
-
Pathogenesis of L-tryptophan eosinophilia myalgia syndrome.Adv Exp Med Biol. 1996;398:325-30. doi: 10.1007/978-1-4613-0381-7_50. Adv Exp Med Biol. 1996. PMID: 8906284 Review.
-
L-tryptophan and the eosinophilia-myalgia syndrome: current understanding of the etiology and pathogenesis.J Invest Dermatol. 1993 Jan;100(1):97S-105S. doi: 10.1111/1523-1747.ep12356368. J Invest Dermatol. 1993. PMID: 8423409 Review.
-
1,1'-Ethylidenebis(tryptophan) (Peak E) induces functional activation of human eosinophils and interleukin 5 production from T lymphocytes: association of eosinophilia-myalgia syndrome with a L-tryptophan contaminant.J Clin Immunol. 1994 Jan;14(1):50-60. doi: 10.1007/BF01541175. J Clin Immunol. 1994. PMID: 8132737
-
Enhanced collagen synthesis and transcription by peak E, a contaminant of L-tryptophan preparations associated with the eosinophilia myalgia syndrome epidemic.J Clin Invest. 1995 Nov;96(5):2120-5. doi: 10.1172/JCI118265. J Clin Invest. 1995. PMID: 7593596 Free PMC article.
-
Eosinophilia-myalgia syndrome: a recent syndrome serving as an alert to new diseases ahead.Mod Pathol. 1994 Sep;7(7):806-10. Mod Pathol. 1994. PMID: 7824518 Review.
Cited by
-
Post-epidemic eosinophilia-myalgia syndrome associated with L-tryptophan.Arthritis Rheum. 2011 Nov;63(11):3633-9. doi: 10.1002/art.30514. Arthritis Rheum. 2011. PMID: 21702023 Free PMC article.
-
Eosinophilic hepatitis: a new feature of the clinical spectrum of the eosinophilia-myalgia syndrome.Clin Rheumatol. 1994 Sep;13(3):528-32. doi: 10.1007/BF02242958. Clin Rheumatol. 1994. PMID: 7835024
-
Pathological and immunological effects of ingesting L-tryptophan and 1,1'-ethylidenebis (L-tryptophan) in Lewis rats.J Clin Invest. 1993 Mar;91(3):804-11. doi: 10.1172/JCI116300. J Clin Invest. 1993. PMID: 8450062 Free PMC article.
-
Chronic fatigue: a peculiar evolution of eosinophilia myalgia syndrome following treatment with L-tryptophan in four Italian adolescents.Eur J Pediatr. 1994 May;153(5):344-6. doi: 10.1007/BF01956416. Eur J Pediatr. 1994. PMID: 8033924
-
A comparative study on antibodies to nucleoli and 5-hydroxytryptamine in patients with fibromyalgia syndrome and tryptophan-induced eosinophilia-myalgia syndrome.Clin Investig. 1994 Jul;72(7):541-9. doi: 10.1007/BF00207485. Clin Investig. 1994. PMID: 7981584 Clinical Trial.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources